Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
212 USD -4.60% Intraday chart for Madrigal Pharmaceuticals, Inc. -10.38% -8.36%
Apr. 11 Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Apr. 11 Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Says Rezdiffra Available in US MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch RE
Madrigal commences $500 million public offering of common stock RE
North American Morning Briefing : Investors -2- DJ
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating MT
Madrigal Pharmaceuticals Gets Added Boost with Rezdiffra Nod From FDA, B. Riley Says MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating MT
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's... Our Logo
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating MT
Old demons return as tech takes a dive Our Logo
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155 MT
Wall St futures mixed as inflation woes weigh RE

Chart Madrigal Pharmaceuticals, Inc.

Chart Madrigal Pharmaceuticals, Inc.
More charts

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
222.3 USD
Average target price
394.5 USD
Spread / Average Target
+77.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MADRIGAL PHARMACEUTICALS, INC. Stock Madrigal Pharmaceuticals, Inc.
-8.36% 4.67B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. News Madrigal Pharmaceuticals, Inc.
  5. Madrigal Pharmaceuticals : Jefferies Starts Madrigal Pharmaceuticals at Buy With $151 Price Target